Intest Res.  2014 Jan;12(1):80-82. 10.5217/ir.2014.12.1.80.

Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study

• Yoon JY
• Park SJ
• Cheon JH

• KMID: 2174344
• DOI: http://doi.org/10.5217/ir.2014.12.1.80

Abstract

No abstract available.

MeSH Terms

Colostrum*
Humans
Irritable Bowel Syndrome*
Permeability*

Figure

• 

  Fig. 1 Comparison of patients in the colostrum and placebo groups using (A) GSRS-IBS and (B) IBS-QOL. GSRS-IBS, gastrointestinal symptom rating scale-irritable bowel syndrome; IBS-QOL, irritable bowel syndrome-quality of life.

• 

  Fig. 2 Comparison of the changes in the endotoxin level between patients in the colostrum and placebo groups.

Reference

1. Drossman DD, Corazziari E, Delvaux M, et al. Rome III: the functional gastrointestinal discorders. 3rd ed. McLean, VA: Degnon Associates, Inc.;2006.

2. Park KS, Ahn SH, Hwang JS, et al. A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients. Dig Dis Sci. 2008; 53:704–711. PMID: 17717743.

3. Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol. 2006; 19:1638–1645. PMID: 17013373.

4. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002; 122:1778–1783. PMID: 12055584.

5. van Deventer SJ, ten Cate JW, Tytgat GN. Intestinal endotoxemia. Clinical significance. Gastroenterology. 1988; 94:825–831. PMID: 3276576.

6. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132:913–920. PMID: 17383420.

7. Uruakpa FO, Ismond MAH, Akobundu ENT. Colostrum and its benefits: a review. Nutr Res. 2002; 22:755–767.

8. Pakkanen R. Determination of transforming growth factor-beta 2 (TGF-beta 2) in bovine colostrum samples. J Immunoassay. 1998; 19:23–37. PMID: 9530609.

9. Playford RJ, Macdonald CE, Johnson WS. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr. 2000; 72:5–14. PMID: 10871554.

10. Rawal P, Gupta V, Thapa BR. Role of colostrum in gastrointestinal infections. Indian J Pediatr. 2008; 75:917–921. PMID: 19011803.

11. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006; 130:1480–1491. PMID: 16678561.

12. Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003; 48:1317–1323. PMID: 12870789.

13. Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003; 38:947–954. PMID: 14531531.

14. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998; 43:400–411. PMID: 9512138.

15. Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol. 2003; 98:122–127. PMID: 12526947.

16. Park JM, Choi MG, Oh JH, et al. Cross-cultural validation of irritable bowel syndrome quality of life in Korea. Dig Dis Sci. 2006; 51:1478–1484. PMID: 16855882.

17. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005; 17:332–340. PMID: 15916620.

18. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003; 52:671–676. PMID: 12692051.